During execution of your IND-enabling program you will benefit from QPS’s operational strengths, strong scientific/regulatory pre-IND/IND support, and drug development experience
SpinAlgo | Algorithm for Energy Performance Assessment for Textile Industry |...Umesh Bhutoria
SpinAlgo is a tool that analyzes basic energy and production data to provide actionable energy performance insights. It reduces the time spent on reporting and analysis by 80% and handles normalization across 20+ energy performance indicators. Key benefits include taking care of historical analysis, operational behavior normalization, and compliance with reporting schemes. SpinAlgo was developed using over 1 million data points from 14+ years of operational data from multiple spinning units, allowing users to focus on implementing insights rather than report preparation.
The document summarizes an energy audit conducted of the Indian Institute of Technology (IIT) Kharagpur campus in India. A team of students and interns led the audit in association with IIT Kharagpur faculty and an energy solutions startup. They divided the campus into areas and collected electrical, fossil fuel, and HVAC usage data. The goal was to identify opportunities to reduce energy consumption and costs while providing learning experiences for those involved.
This document discusses energy management and ISO 50001, an international standard for energy management systems. It provides an overview of global energy trends showing increasing demand, the benefits organizations have realized from effective energy management in cost savings, and the key elements of an energy management system based on ISO 50001 including establishing baselines and goals, implementing action plans, monitoring performance, and continually improving the system. ISO 50001 provides a framework to help organizations systematically improve energy efficiency and reduce costs.
This document discusses energy management and provides tips for improving energy efficiency. It notes that the biggest energy wasters are fuel used for operations and HVAC systems, and electricity usage. Reasons to focus on energy efficiency include legal requirements, costs savings, and environmental impacts. The document recommends auditing current energy usage, focusing on easy fixes like policies and upgrades. Larger projects should be researched for costs and benefits. Tracking achievements can help motivate staff and stakeholders to continually improve energy management.
The document provides an overview of energy management and energy audits. It defines energy and various types of energy like mechanical, thermal, nuclear, chemical, and electromagnetic. Energy management aims to optimize energy use and reduce costs. The objectives are to minimize energy procurement and utilization costs without affecting production. Energy audits identify ways to reduce energy consumption per unit of output. Preliminary audits establish baseline consumption while detailed audits evaluate all energy consuming systems and equipment to identify savings opportunities through a ten step process. The document outlines the various instruments used in energy audits to measure consumption.
- Energy management standards like ISO 50001 provide organizations with guidelines for improving energy efficiency. International groups like ISO and CEN develop these standards to benefit business and society. ISO 50001 has become the global best practice for energy management systems, helping companies save 5-37% on energy costs. Adopting ISO 50001 provides benefits like reduced costs and carbon emissions as well as increased credibility. Many successful companies have certified to ISO 50001 and achieved significant energy and financial savings as a result.
ISO 50001 provides a framework for organizations to establish an energy management system to improve energy performance including energy efficiency. It helps companies reduce energy costs, better utilize existing energy-consuming assets, and facilitate transparency in energy resource management. Implementing ISO 50001 involves establishing an energy policy, conducting an energy review to establish a baseline and indicators, implementing a plan to improve energy performance through the PDCA cycle, and continually reviewing and improving the EnMS.
A public work I developed while under contract with UL to build and operate their Sustainability and energy Practice across the US, global offices and management consultant base.
Created as a management consulting tool for "C" Suite executives to guide in strategy development, launch, operation, and assessment of internal programs controlling all forms of energy, behavioral or engineering based projects.
SpinAlgo | Algorithm for Energy Performance Assessment for Textile Industry |...Umesh Bhutoria
SpinAlgo is a tool that analyzes basic energy and production data to provide actionable energy performance insights. It reduces the time spent on reporting and analysis by 80% and handles normalization across 20+ energy performance indicators. Key benefits include taking care of historical analysis, operational behavior normalization, and compliance with reporting schemes. SpinAlgo was developed using over 1 million data points from 14+ years of operational data from multiple spinning units, allowing users to focus on implementing insights rather than report preparation.
The document summarizes an energy audit conducted of the Indian Institute of Technology (IIT) Kharagpur campus in India. A team of students and interns led the audit in association with IIT Kharagpur faculty and an energy solutions startup. They divided the campus into areas and collected electrical, fossil fuel, and HVAC usage data. The goal was to identify opportunities to reduce energy consumption and costs while providing learning experiences for those involved.
This document discusses energy management and ISO 50001, an international standard for energy management systems. It provides an overview of global energy trends showing increasing demand, the benefits organizations have realized from effective energy management in cost savings, and the key elements of an energy management system based on ISO 50001 including establishing baselines and goals, implementing action plans, monitoring performance, and continually improving the system. ISO 50001 provides a framework to help organizations systematically improve energy efficiency and reduce costs.
This document discusses energy management and provides tips for improving energy efficiency. It notes that the biggest energy wasters are fuel used for operations and HVAC systems, and electricity usage. Reasons to focus on energy efficiency include legal requirements, costs savings, and environmental impacts. The document recommends auditing current energy usage, focusing on easy fixes like policies and upgrades. Larger projects should be researched for costs and benefits. Tracking achievements can help motivate staff and stakeholders to continually improve energy management.
The document provides an overview of energy management and energy audits. It defines energy and various types of energy like mechanical, thermal, nuclear, chemical, and electromagnetic. Energy management aims to optimize energy use and reduce costs. The objectives are to minimize energy procurement and utilization costs without affecting production. Energy audits identify ways to reduce energy consumption per unit of output. Preliminary audits establish baseline consumption while detailed audits evaluate all energy consuming systems and equipment to identify savings opportunities through a ten step process. The document outlines the various instruments used in energy audits to measure consumption.
- Energy management standards like ISO 50001 provide organizations with guidelines for improving energy efficiency. International groups like ISO and CEN develop these standards to benefit business and society. ISO 50001 has become the global best practice for energy management systems, helping companies save 5-37% on energy costs. Adopting ISO 50001 provides benefits like reduced costs and carbon emissions as well as increased credibility. Many successful companies have certified to ISO 50001 and achieved significant energy and financial savings as a result.
ISO 50001 provides a framework for organizations to establish an energy management system to improve energy performance including energy efficiency. It helps companies reduce energy costs, better utilize existing energy-consuming assets, and facilitate transparency in energy resource management. Implementing ISO 50001 involves establishing an energy policy, conducting an energy review to establish a baseline and indicators, implementing a plan to improve energy performance through the PDCA cycle, and continually reviewing and improving the EnMS.
A public work I developed while under contract with UL to build and operate their Sustainability and energy Practice across the US, global offices and management consultant base.
Created as a management consulting tool for "C" Suite executives to guide in strategy development, launch, operation, and assessment of internal programs controlling all forms of energy, behavioral or engineering based projects.
QPS DMPK provides a dedicated team of senior scientists to help select, design and conduct the appropriate ADME studies
for your specific compounds and therapeutic targets.
Working with QPS DMPK is a collaborative and consultative
endeavor that also incorporates our operational effectiveness
and dedication to customer service.
Whether your focus is on small molecules, proteins, bio-therapeutics, vaccines, or gene therapy, QPS provides a full range of bioanalytical solutions to support drug development from discovery through clinical development and filing.
At QPS, translational medicine brings together leading-edge technologies and pharmaceutical research and development experience to create a business service unit that works efficiently to advance your drug development program.
Our profound expertise in Neuroscience and two decades of experience in contract research result in a sustainable advantage for our customers. QPS offers you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models to guarantee that your new chemical or biological compounds are profiled in depth.
The QPS Bioanalysis General presentation is a summary of our capabilities in Neuropharmacology, Toxicology, DMPK, Bioanalytical, Translational Medicine, and Dermal and Transdermal Preclinical services.
This document discusses cerebrospinal fluid (CSF) sampling services provided by QPS Netherlands. CSF sampling can provide pharmacokinetic data about drug concentrations in the central nervous system. QPS Netherlands has the capability to perform CSF sampling procedures under clinical trial conditions in compliance with regulations. Their proximity to a university medical center allows for efficient CSF sample collection and analysis of biomarkers to support drug development studies.
When your focus is Biotherapeutics, QPS’ Global Laboratories provide a full range of bioanalytical solutions to support immunogenicity evaluations during drug development from discovery through clinical development and filing.
Partnering with QPS for a well-conceived and executed IND-enabling preclinical program will provide you with a detailed
assessment of your drug candidate and the most agile, flexible and timely pathway to filing an IND.
QPS Missouri's Negative Pressure Room.
A negative pressure room uses lower air pressure than the
rooms surrounding it to allow outside air into the facility.
This traps and keeps harmful particles from leaving the
potentially contaminated area.
A well-conceived and executed preclinical and clinical
radiolabeled ADME program will provide you with a detailed
assessment of the total fate (mass balance, route, and rate of excretion,
tissue distribution, metabolic pathways, and identity and quantity of
metabolites) of your drug candidate to support regulatory submissions.
QPS Regulated Bioanalysis of Antibody Drug ConjugatesQPS Holdings, LLC
PK profiling reflects molecular complexity. Since 2001 QPS’ bioanalytical teams have contributed to ADC drug development,
supporting the filing of one of the first drug targeting
programs and continue to develop customized
strategies for novel conjugate molecules.
To support research and development in different stages of biopharmaceutical compounds and products, QPS offers biomarker services in different global competence centers using
a wide range of technology platforms to support programs in any therapeutic area. QPS biomarker capabilities range from small molecule analysis to whole cell characterization.
When your focus is small molecules, biomarkers, or protein biotherapeutics,
QPS’ LC-MS/MS laboratories provide a full range of
bioanalytical solutions to support drug development
from discovery through clinical development.
This document outlines key milestones in the development and approval of gene therapy products from 1998 to 2020. It shows the year of important bioanalytical methods being applied to oligonucleotides and vectors used in gene therapy, as well as the year of approval for several gene therapy products that work via different mechanisms such as gene interference using antisense oligonucleotides, aptamers, or small interfering RNA, and gene insertion using viral vectors like adeno-associated virus or lentivirus. The most recent approvals in 2019-2020 include gene therapies to treat spinal muscular atrophy and beta-thalassemia.
This document provides an overview of assay technologies and milestones for a biopharmaceutical company from 1996 to 2020. It includes information on cytokine release assays, GLP, GMP, and CLIA compliance as well as platforms for analyzing biomarkers, genetics, small molecules, proteins, gene therapy, and more with techniques such as QPCR, flow cytometry, mass spectrometry, and immunoassays. Key developments include new assays for peptides, oligonucleotides, antibodies, and viral detection.
This white paper focuses on overcoming the challenges of participating in a pediatric trial. One of the biggest issues is that it is difficult to enroll participants in pediatric trials. Read these 5 strategies to help make it easier to enroll trial participants and complete successful trials.
QPS is a contract research organization that specializes in developing close relationships with clients based on trust and mutual respect. They offer flexible and nimble clinical work to improve outsourced work quality and reduce oversight needs. Their biosimilar drug development expertise can help clients advance their biosimilar portfolios in a timely manner for the benefit of patients worldwide.
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS DisordersQPS Holdings, LLC
"Developing therapies for diseases of the central nervous system (CNS) presents special challenges directly related to the complexity of the human brain and its function of integrating our communications with the outside world. Animal models of human neurological and psychiatric disorders are scarce, because many of these human diseases do not naturally occur in animals, and their study necessitates either specific manipulation (induced models) or the production of genetically modified rodents (transgenic and KO models). Even with these models, it remains unclear, what behavioral domain really resembles higher brain function in humans, and how we can interpret animal data on cognition, emotion, social interaction or activities of daily living.
Furthermore, in contrast with other organs, the CNS is sequestered from the general circulation by the blood brain barrier (BBB), potentially preventing many compounds from reaching their intended target. Quantifying how much of and how long a compound resides in the CNS is difficult and indirect. Therefore, the assessment of target engagement calls for specific techniques and know-how. While animal models provide some information as to how well a given compound accesses the brain, this data cannot always be translated directly to humans. Insufficient knowledge of target-compound interaction may be a major cause of failure in drug development for CNS disorders.
QPS understands the specific challenges of translation from animal models to human clinical application. Our extensive experience in CNS affords us a clear view of its complexities and its current global clinical study environment. Our direct links with the international scientific community and close relationships with key opinion leaders worldwide, together with our dedicated experts, original strategies and operational transparency, are keys to the effective execution of CNS programs for our clients."
The Nobel Prize for the discovery that double-stranded RNAs (dsRNAs) can trigger silencing of complementary messenger RNA sequences was awarded in 1998 and the term ‘RNA interference’ (RNAi) was born, opening the door to a completely novel and untapped market within the pharmaceutical industry. Shortly thereafter, short dsRNAs — or short interfering RNAs (siRNAs) — were generated artificially and used to demonstrate that this process also occurs in mammalian cells. The knowledge that small strands of RNAs can affect gene expression has had a tremendous impact on basic and applied research, and RNAi is currently one of the most promising new approaches for disease therapy. In 2004, only six years after the discovery of RNAi, the first siRNA-based human therapeutics — developed to treat wet age-related macular degeneration — entered phase I clinical trials. RNAi is one of the fastest advancing fields in biology, and the flow of discovery gives true meaning to the expression ‘from the bench to the bedside'.
QPS DMPK provides a dedicated team of senior scientists to help select, design and conduct the appropriate ADME studies
for your specific compounds and therapeutic targets.
Working with QPS DMPK is a collaborative and consultative
endeavor that also incorporates our operational effectiveness
and dedication to customer service.
Whether your focus is on small molecules, proteins, bio-therapeutics, vaccines, or gene therapy, QPS provides a full range of bioanalytical solutions to support drug development from discovery through clinical development and filing.
At QPS, translational medicine brings together leading-edge technologies and pharmaceutical research and development experience to create a business service unit that works efficiently to advance your drug development program.
Our profound expertise in Neuroscience and two decades of experience in contract research result in a sustainable advantage for our customers. QPS offers you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models to guarantee that your new chemical or biological compounds are profiled in depth.
The QPS Bioanalysis General presentation is a summary of our capabilities in Neuropharmacology, Toxicology, DMPK, Bioanalytical, Translational Medicine, and Dermal and Transdermal Preclinical services.
This document discusses cerebrospinal fluid (CSF) sampling services provided by QPS Netherlands. CSF sampling can provide pharmacokinetic data about drug concentrations in the central nervous system. QPS Netherlands has the capability to perform CSF sampling procedures under clinical trial conditions in compliance with regulations. Their proximity to a university medical center allows for efficient CSF sample collection and analysis of biomarkers to support drug development studies.
When your focus is Biotherapeutics, QPS’ Global Laboratories provide a full range of bioanalytical solutions to support immunogenicity evaluations during drug development from discovery through clinical development and filing.
Partnering with QPS for a well-conceived and executed IND-enabling preclinical program will provide you with a detailed
assessment of your drug candidate and the most agile, flexible and timely pathway to filing an IND.
QPS Missouri's Negative Pressure Room.
A negative pressure room uses lower air pressure than the
rooms surrounding it to allow outside air into the facility.
This traps and keeps harmful particles from leaving the
potentially contaminated area.
A well-conceived and executed preclinical and clinical
radiolabeled ADME program will provide you with a detailed
assessment of the total fate (mass balance, route, and rate of excretion,
tissue distribution, metabolic pathways, and identity and quantity of
metabolites) of your drug candidate to support regulatory submissions.
QPS Regulated Bioanalysis of Antibody Drug ConjugatesQPS Holdings, LLC
PK profiling reflects molecular complexity. Since 2001 QPS’ bioanalytical teams have contributed to ADC drug development,
supporting the filing of one of the first drug targeting
programs and continue to develop customized
strategies for novel conjugate molecules.
To support research and development in different stages of biopharmaceutical compounds and products, QPS offers biomarker services in different global competence centers using
a wide range of technology platforms to support programs in any therapeutic area. QPS biomarker capabilities range from small molecule analysis to whole cell characterization.
When your focus is small molecules, biomarkers, or protein biotherapeutics,
QPS’ LC-MS/MS laboratories provide a full range of
bioanalytical solutions to support drug development
from discovery through clinical development.
This document outlines key milestones in the development and approval of gene therapy products from 1998 to 2020. It shows the year of important bioanalytical methods being applied to oligonucleotides and vectors used in gene therapy, as well as the year of approval for several gene therapy products that work via different mechanisms such as gene interference using antisense oligonucleotides, aptamers, or small interfering RNA, and gene insertion using viral vectors like adeno-associated virus or lentivirus. The most recent approvals in 2019-2020 include gene therapies to treat spinal muscular atrophy and beta-thalassemia.
This document provides an overview of assay technologies and milestones for a biopharmaceutical company from 1996 to 2020. It includes information on cytokine release assays, GLP, GMP, and CLIA compliance as well as platforms for analyzing biomarkers, genetics, small molecules, proteins, gene therapy, and more with techniques such as QPCR, flow cytometry, mass spectrometry, and immunoassays. Key developments include new assays for peptides, oligonucleotides, antibodies, and viral detection.
This white paper focuses on overcoming the challenges of participating in a pediatric trial. One of the biggest issues is that it is difficult to enroll participants in pediatric trials. Read these 5 strategies to help make it easier to enroll trial participants and complete successful trials.
QPS is a contract research organization that specializes in developing close relationships with clients based on trust and mutual respect. They offer flexible and nimble clinical work to improve outsourced work quality and reduce oversight needs. Their biosimilar drug development expertise can help clients advance their biosimilar portfolios in a timely manner for the benefit of patients worldwide.
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS DisordersQPS Holdings, LLC
"Developing therapies for diseases of the central nervous system (CNS) presents special challenges directly related to the complexity of the human brain and its function of integrating our communications with the outside world. Animal models of human neurological and psychiatric disorders are scarce, because many of these human diseases do not naturally occur in animals, and their study necessitates either specific manipulation (induced models) or the production of genetically modified rodents (transgenic and KO models). Even with these models, it remains unclear, what behavioral domain really resembles higher brain function in humans, and how we can interpret animal data on cognition, emotion, social interaction or activities of daily living.
Furthermore, in contrast with other organs, the CNS is sequestered from the general circulation by the blood brain barrier (BBB), potentially preventing many compounds from reaching their intended target. Quantifying how much of and how long a compound resides in the CNS is difficult and indirect. Therefore, the assessment of target engagement calls for specific techniques and know-how. While animal models provide some information as to how well a given compound accesses the brain, this data cannot always be translated directly to humans. Insufficient knowledge of target-compound interaction may be a major cause of failure in drug development for CNS disorders.
QPS understands the specific challenges of translation from animal models to human clinical application. Our extensive experience in CNS affords us a clear view of its complexities and its current global clinical study environment. Our direct links with the international scientific community and close relationships with key opinion leaders worldwide, together with our dedicated experts, original strategies and operational transparency, are keys to the effective execution of CNS programs for our clients."
The Nobel Prize for the discovery that double-stranded RNAs (dsRNAs) can trigger silencing of complementary messenger RNA sequences was awarded in 1998 and the term ‘RNA interference’ (RNAi) was born, opening the door to a completely novel and untapped market within the pharmaceutical industry. Shortly thereafter, short dsRNAs — or short interfering RNAs (siRNAs) — were generated artificially and used to demonstrate that this process also occurs in mammalian cells. The knowledge that small strands of RNAs can affect gene expression has had a tremendous impact on basic and applied research, and RNAi is currently one of the most promising new approaches for disease therapy. In 2004, only six years after the discovery of RNAi, the first siRNA-based human therapeutics — developed to treat wet age-related macular degeneration — entered phase I clinical trials. RNAi is one of the fastest advancing fields in biology, and the flow of discovery gives true meaning to the expression ‘from the bench to the bedside'.
This presentation delves into the core principles of personality development as taught by Tim Han. Understand the importance of self-awareness, goal setting, and maintaining a positive attitude. Gain valuable tips on improving communication skills and developing emotional intelligence. Tim Han’s practical advice and holistic approach will help you embark on a transformative journey towards becoming your best self.
Stealth attraction for mens gets her with your wordsichettrisagar95
My article gives a set of techniques used by men to subtly and effectively attract women without overtly displaying their intentions. It involves using non-verbal cues, body language, and subtle psychological tactics to create intrigue and build attraction. The goal is to appear confident, mysterious, and charismatic while maintaining an air of mystery that piques the interest of the person you are trying to attract. This approach emphasizes subtlety and finesse in communication and interaction to create a powerful and lasting impression.